

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
02 March 2023 (02.03.2023)



(10) International Publication Number  
**WO 2023/028564 A1**

(51) International Patent Classification:

C07D 209/96 (2006.01) C07D 409/06 (2006.01)  
C07D 401/06 (2006.01) C07D 409/12 (2006.01)  
C07D 401/12 (2006.01) C07D 409/14 (2006.01)  
C07D 401/14 (2006.01) C07D 413/12 (2006.01)  
C07D 403/10 (2006.01) C07D 491/107 (2006.01)  
C07D 403/12 (2006.01) C07D 491/22 (2006.01)  
C07D 405/06 (2006.01) C07F 9/53 (2006.01)  
C07D 405/12 (2006.01) A61P 35/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/075472

(22) International Filing Date:

25 August 2022 (25.08.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/237,275 26 August 2021 (26.08.2021) US  
63/306,452 03 February 2022 (03.02.2022) US  
63/344,435 20 May 2022 (20.05.2022) US


(71) Applicant: **VOLASTRA THERAPEUTICS, INC.**  
[US/US]; 1361 Amsterdam Avenue, Suite 520, New York,  
New York 10027 (US).

(72) Inventor: **COGAN, Derek A.**; c/o Volastra Therapeutics,  
Inc., 1361 Amsterdam Avenue, Suite 520, New York, New  
York 10027 (US).

(74) Agent: **MCCRUDDEN, Garreth et al.**; 425 Market Street,  
San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: SPIRO INDOLINE INHIBITORS OF KIF18A



(57) Abstract: The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.

WO 2023/028564 A1